secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2024-02-02T23:59:59+00:00
Accession:  0001601485-24-000013
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elicio raises CEO/CSO base pay, grants 225k/30k stock options, adopts severance plan
--------------------------------------------------------------------------------

- CEO base salary raised to $608,400; annual performance bonus opportunity set at 55% of base.
- CSO base salary increased to $460,000; annual performance bonus opportunity set at 40% of base.
- Stock options granted: 225,137 shares to CEO, 29,800 shares to CSO; vest 25% on first anniversary then monthly.
- New Executive Severance Plan provides salary-based multipliers for normal and change-in-control severance, plus equity acceleration.
- Severance benefits require a release and are conditioned on compliance with restrictive covenants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000160148524000013/0001601485-24-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000160148524000013/angn-20240201.htm
  HTML page:      https://secwatch.observer/filing/0001601485-24-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer